All data considered, the benefit of the therapy, Oxbryta, “no longer outweighs the risk,” Pfizer said in a statement ...

U.S. drugmaker Pfizer said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where ...

Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed ...

European Union suspends Pfizer's Oxbryta for sickle cell disease due to safety concerns, urging doctors to stop use ...

Based on new safety signals, Pfizer on Wednesday announced that Oxbryta’s overall benefit “no longer outweighs the risk” in ...

Pfizer is pulling its sickle cell disease (SCD) treatment voxelotor (Oxbryta) from global markets after data review showed an ...

The US big pharma company Pfizer has voluntarily withdrawn the oral sickle cell disease treatment Oxbryta from the market and ...

Pfizer Inc. (NYSE:PFE) said the company is voluntarily withdrawing all lots of Oxbryta (voxelotor) for the treatment of ...

The healthcare company said clinical data indicates the overall benefit of Oxbryta no longer outweighs the risk in the ...

Pfizer has announced the voluntary withdrawal of all lots of OXBRYTA (voxelotor) approved for treating sickle cell disease ...

It's a blow to the SCD community, as Oxbryta (voxelotor) was the first drug to reach the market that prevented sickle ...